ESSENCE Study: Does the Drug Semaglutide Work in People With NASH?
Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!
a study on Nonalcoholic Steatohepatitis Steatohepatitis Liver Disease Nonalcoholic Fatty Liver Disease
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UC Davis UCSD UCSF
- Dates
- study startedcompletion around
Description
Summary
Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries.
Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance.
Participants will need to inject themselves with medicine under the skin. Participants will need to do this once a week.
The study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day.
Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.
Official Title
The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis
Keywords
Non-alcoholic Steatohepatitis, Fatty Liver, Non-alcoholic Fatty Liver Disease, Semaglutide
Eligibility
You can join if…
Open to people ages 18 years and up
- Age above or equal to 18 years at the time of signing informed consent.
- Histological evidence of NASH based on a central pathologist evaluation of the baseline liver biopsy. The baseline liver biopsy can be a historical biopsy obtained within 180 days prior to the screening visit (V1).
- Histological evidence of fibrosis stage 2 or stage 3 according to the NASH CRN (Clinical Research Network) classification based on a central pathologist evaluation of the baseline liver biopsy.
- A histological NAS (Non-alcoholic fatty liver disease Activity Score) above or equal to 4 with a score of 1 or more in steatosis, lobular inflammation and hepatocyte ballooning based on a central pathologist evaluation of the baseline liver biopsy.
You CAN'T join if...
- Documented causes of chronic liver disease other than non-alcoholic fatty liver disease (NAFLD)
- Positive HBsAg, positive anti-HIV, positive HCV RNA at screening (V2A) or any known presence of HCV RNA or HBsAg within 2 years of screening (V2A).
- Presence or history of ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis or liver transplantation at randomisation.
- Known or suspected excessive consumption of alcohol (greater than 20 g/day for women or greater than 30 g/day for men) or alcohol dependence (assessed by the Alcohol Use Disorders Identification Test (AUDIT questionnaire)).
- Treatment with vitamin E (at doses greater than or equal to 800 IU/day) or pioglitazone or medications approved for treatment of NASH which has not been at a stable dose in the period from 90 days prior to the screening visit (V2A). In addition, for subjects with historical liver biopsies taken more than 90 days prior to screening, treatment should be at a stable dose from time of biopsy until screening.
- Treatment with GLP-1 RAs in the period from 90 days prior to the screening visit (V2A). In addition, for subjects with historical liver biopsies taken more than 90 days prior to screening, any treatment with GLP-1 RAs from time of biopsy until screening (V2A).
- Treatment with glucose-lowering agent(s) (other than GLP-1 RAs), lipid-lowering medication or weight loss medication not stable in the opinion of the investigator in the period from 90 days prior to the screening visit (V2A). In addition, for subjects with historical liver biopsies taken more than 90 days prior to screening, treatment should be at a stable dose in the opinion of the investigator from time of biopsy until screening.
Locations
- UCSD NAFLD Research Center
accepting new patients
La Jolla California 92037 United States - UC Davis Hlth -Midtwn Ambu Cen
accepting new patients
Sacramento California 95817 United States - University of California, San Francisco
accepting new patients
San Francisco California 94143-0780 United States - Scripps Whittier Diabetes Inst
withdrawn
La Jolla California 92037 United States - Cedars-Sinai Medical Center
currently not accepting new patients, but might later
Pasadena California 90048 United States - Pasedena Liver Center
accepting new patients
Pasadena California 91105 United States - Gastroenterology & Liver Institute
accepting new patients
Escondido California 92025 United States - Digestive Hlth Res of SoCa
accepting new patients
Long Beach California 90808 United States - Shang Wu M.D. Inc.
withdrawn
Hacienda Heights California 91745 United States
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Novo Nordisk A/S
- ID
- NCT04822181
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 1200 study participants
- Last Updated